Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allogeneic CD19-STAR T cell
- Development stage
- Phase 2
- Lead developer
- BriSTAR Immunotech
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic CD19-STAR T cell is an investigational allogeneic T cell therapy developed for patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (B-NHL). This therapy involves synthetic T cell receptor (TCR) and antigen receptor (STAR) T cells, which are derived from healthy donors. The T cells are engineered using CRISPR-Cas9 gene editing to simultaneously knock out endogenous T cell receptor alpha constant (TRAC), human leukocyte antigen (HLA)-A/B, CIITA, and programmed death 1 (PD-1) genes. The STAR molecule is integrated into the TRAC locus. This strategic genetic modification aims to mitigate graft-versus-host-disease (GvHD) toxicity and host-versus-graft response, reduce the sensitivity of STAR T cells to immunosuppressive signals, and enhance their anti-tumor activity.
- Other names
- Allogeneic CD19-targeting STAR T cellsAllogeneic TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor (STAR) T Cells
02
Targets
Beyond the preview
Go deeper on Allogeneic CD19-STAR T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allogeneic CD19-STAR T cell.